Looking Forward to Good Things for Patients with Relapsed/Refractory Myeloma!

| Michael Tuohy

Today is only half over, and we’ve already heard fantastic presentations. I’ll focus on just two of them here and direct you to the other leader’s blogs for a full picture of this jam-packed day of oral presentations, a scientific program, and much more.

Eloquent-2 Update, a Phase 3, randomized, open-label study of Empliciti (elotuzumab) in combination with Revlimid® (lenalidomide)/dexamethasone in patients with relapsed/refractory myeloma (RRMM). This trial was presented by Dr. Meletios-Athanassios Dimopoulos, Alexandra Hospital, Athens, Greece. This was a three-year safety and efficacy follow-up.

Empliciti (elotuzumab) is an immunostimulatory monoclonal antibody that recognizes SLAMF7, a protein highly expressed by myeloma and natural killer cells. It causes myeloma cell death via a dual mechanism of action: directly activating natural killer cells and tagging for recognition.


Take home points:

  • Empliciti (elotuzumab) in combination with Revlimid® (lenalidomide) demonstrated a durable and clinically relevant improvement in progression free survival (PFS) and overall response rate (ORR).
  • The FDA recently granted approval for the use Empliciti (elotuzumab) in combination with Revlimid® (lenalidomide)/dexamethasone in patients with myeloma who received one to three prior therapies.

This is particularly exciting since I’ve been on Revlimid® (lenalidomide)/dexamethasone for 10 years now. This may mean that upon relapse, adding Empliciti (elotuzumab) to my Revlimid® (lenalidomide)/dexamethasone regimen may help to extend my good results.

The next trial I’ll report on is:

Clinical Efficacy of Darzalex (daratumumab) Monotherapy in Patients with Heavly Pre-treated Relapsed or Refractory Multiple Myeloma (RRMM). This trial was presented by Dr. Saad Usmani, Charlotte, North Carolina.

Darzalex (daratumumab)’s mechanisms of action:

  • CD38 is highly expressed on myeloma cells
  • DARA is a human monoclonal antibody that binds CD38-expressing cells
  • DARA is binding to CD38 induces tumor cell death through direct and indirect mechanisms

Take Home Points:

  • As a single agent, DARA induced rapid, deep, and durable responses in a heavily pretreated/highly refractory population.

In refractory MM patients, a remarkable depth of response has been observed to newer agents, including Pomalyst® (pomalidomide) and Kyprolis® (carfilzomib).

  • DARA had an overall survival (OS) benefit even in patients who achieved stable disease or minimal response.

This is also very hopeful as patients in RRMM have a fantastic single agent option!

Now I’m off to the IMF’s Grant Awards and Media Event!

Follow Michael on Twitter: @IMFmikeMYELOMA
Connecticut Multiple Myeloma Fighters Information Group
Waterbury, CT

Leave a Reply